Details of the Drug

General Information of Drug (ID: DMOQ81Y)

Drug Name

Vernakalant

Synonyms

Vernakalant; 794466-70-9; UNII-9G468C8B13; Vemakalant; RSD1235; 9G468C8B13; (3R)-1-((1R,2R)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)pyrrolidin-3-ol; 3-Pyrrolidinol,1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]-, (3R)-; RSD-1235; Vernakalant [INN:BAN]; SCHEMBL410062; CHEMBL2111112; DTXSID60229659; VBHQKCBVWWUUKN-KZNAEPCWSA-N; CHEBI:135956; EX-A2465; ZINC22010910; 4151AH; AKOS027326205; DB06217; SB16873; CS-0276; API0014187; RL05068; 3-Pyrrolidinol, 1-((1R,2R)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)-, (3R)-

Indication

Disease Entry	ICD 11	Status	REF
Atrial fibrillation	BC81.3	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

349.5

Logarithm of the Partition Coefficient (xlogp)

2.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 3.9 mg/L [2]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 10 min [2]
Clearance: The total body clearance of drug is 0.41 L/h/kg []
Half-life: The concentration or amount of drug in body reduced by one-half in 3 hours [3]
Metabolism: The drug is metabolized via the CYP2D6 mediated O-demethylation []
Vd: The volume of distribution (Vd) of drug is approximately 2 L/kg []

Chemical Identifiers

Formula: C20H31NO4
IUPAC Name: (3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]pyrrolidin-3-ol
Canonical SMILES: COC1=C(C=C(C=C1)CCO[C@@H]2CCCC[C@H]2N3CC[C@H](C3)O)OC
InChI: InChI=1S/C20H31NO4/c1-23-19-8-7-15(13-20(19)24-2)10-12-25-18-6-4-3-5-17(18)21-11-9-16(22)14-21/h7-8,13,16-18,22H,3-6,9-12,14H2,1-2H3/t16-,17-,18-/m1/s1
InChIKey: VBHQKCBVWWUUKN-KZNAEPCWSA-N

Cross-matching ID

PubChem CID: 9930049
ChEBI ID: CHEBI:135956
CAS Number: 794466-70-9
DrugBank ID: DB06217
TTD ID: D00OTL
INTEDE ID: DR1682

Molecular Interaction Atlas of This Drug

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[4]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008 Mar 25;117(12):1518-25.
2	European Medicines Agency Summary of product characteristics
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors. J Clin Pharmacol. 2009 Jan;49(1):17-29.